Dr. Shah is a Board-Certified Adult Endocrinologist and an Associate Professor at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus. His research is focused on improving glycemic control and reducing complications, with special interest in fracture prevention, in people with type 1 diabetes.
Dr. Shah has served as principal investigator on several clinical trials of diabetes technologies and therapeutics such as REPLACE BG, WISDM, Dexcom G6 pivotal study, and insulet' OP5 HCL clinical trial. He has recently published recommendations on standarizing closed-loop system reporting to make these devices downloads easy for patients and providers to understand and optimize glycemic control.
Dr. Shah has served on many leadership positions such as steering committee member for T1D Exchange Clinic Registry (2016-2017), Communication director for diabetes technology interest group at the American Diabetes Association (2019-2020), Ad hoc member of 79th AD annual meeting planning subcommittee for Diabetes Technology, and American College of Endocrinology Self-Assessment Program writing committee member (202-2021). He is well published with over 100 research publications including original article, invited reviews, editorials, and book chapters. He is reviewer for many peer-reviewed indexed journals and grant reviewer for JDRF, ADA and NIH.